Efficacy and safety of second photodynamic therapy for local failure after salvage photodynamic therapy for esophageal cancer

被引:13
|
作者
Yamashita, Hiroki [1 ]
Kadota, Tomohiro [1 ]
Minamide, Tatsunori [1 ]
Sunakawa, Hironori [1 ]
Sato, Daiki [1 ]
Takashima, Kenji [1 ]
Nakajo, Keiichiro [1 ]
Murano, Tatsuro [1 ]
Shinmura, Kensuke [1 ]
Yoda, Yusuke [1 ]
Ikematsu, Hiroaki [1 ]
Yano, Tomonori [1 ]
机构
[1] Natl Canc Ctr Hosp East, Dept Gastroenterol & Endoscopy, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan
关键词
chemoradiotherapy; esophageal squamous cell carcinoma; photodynamic therapy; salvage treatment; talaporfin sodium; SQUAMOUS-CELL CARCINOMA; PHASE-II; DEFINITIVE CHEMORADIOTHERAPY; TRIAL; 5-FLUOROURACIL; RADIOTHERAPY; CISPLATIN; RESECTION; LASER;
D O I
10.1111/den.14072
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objectives Photodynamic therapy (PDT) is an optional salvage treatment for local failure of esophageal squamous cell carcinoma (ESCC) after chemoradiotherapy; however, local failure after PDT sometimes occurs. In such cases, second PDT is sometimes attempted, but its outcomes remain unclear. This study aimed to evaluate the efficacy and safety of second PDT. Methods We enrolled patients who underwent PDT for local failure of ESCC after chemoradiotherapy. We retrospectively evaluated local-complete response (L-CR) rate and clinical outcomes of first and second PDT. The indications for PDT were lesions within the muscle layer, <3 cm in size, and <3/4 of the esophageal circumference; not suitable for salvage surgery; and absence of metastasis. Second PDT was avoided when lesions were apparently refractory to first PDT, e.g. persistence of submucosal tumor-like protruded component or rapid regrowth of tumor at the ulceration after first PDT. L-CR was defined as endoscopic disappearance of tumor and post-PDT ulcer and absence of cancer cells histologically. Results Among 82 patients who underwent first PDT, 27 underwent second PDT. The L-CR rates with first and second PDT were 63.0% and 40.7%, respectively. The 2-year overall survival rates after second PDT in patients with L-CR and local-nonCR were 79.5% and 40.5%, respectively. Five of 11 patients with L-CR survived without any recurrence. No grade >= 3 adverse events occurred. Conclusions Second PDT demonstrated excellent safety and acceptable efficacy; therefore, it could be a useful treatment for local failure after first PDT.
引用
收藏
页码:488 / 496
页数:9
相关论文
共 50 条
  • [21] Combination of photodynamic therapy and endoscopic mucosal resection for recurrent esophageal squamous cell carcinoma after chemoradiotherapy
    Sato, Hidenori
    Hikichi, Takuto
    Kato, Tsunetaka
    Nakamura, Jun
    Hashimoto, Minami
    Kobashi, Ryoichiro
    Yanagita, Takumi
    Takasumi, Mika
    Kobayakawa, Masao
    Ohira, Hiromasa
    CLINICAL JOURNAL OF GASTROENTEROLOGY, 2022, 15 (06) : 1035 - 1040
  • [22] Clinical Impact of the Charlson Comorbidity Index on the Efficacy of Salvage Photodynamic Therapy Using Talaporfin Sodium for Esophageal Cancer
    Kai, Kengo
    Nakashima, Koji
    Kawakami, Hiroshi
    Takeno, Shinsuke
    Hishikawa, Yoshitaka
    Ikenoue, Makoto
    Hamada, Takeomi
    Imamura, Naoya
    Shibata, Tomotaka
    Noritomi, Tomoaki
    Sasaki, Fumisato
    Nakamura, Yoshitaka
    Nanashima, Atsushi
    INTERNAL MEDICINE, 2024, 63 (07) : 903 - 910
  • [23] PHOTODYNAMIC THERAPY OF ESOPHAGEAL CANCER
    MOGHISSI, K
    DIXON, K
    HUDSON, E
    STRINGER, M
    LASERS IN MEDICAL SCIENCE, 1995, 10 (01) : 67 - 71
  • [24] Assessment of photodynamic therapy as a salvage treatment for local failure after chemoradiotherapy or radiotherapy for esophageal cancer in patients aged 80 years or older
    Nishikawa, Michiko
    Yamamoto, Yoshinobu
    Kushida, Saeko
    Hirabayashi, Taku
    Tanaka, Syunta
    Takegawa, Naoki
    Mimura, Takuya
    Tsumura, Hidetaka
    Miki, Ikuya
    Tsuda, Masahiro
    DEN OPEN, 2023, 3 (01):
  • [25] Salvage Endoscopic Submucosal Dissection for Local Recurrence of Superficial Esophageal Squamous Cell Cancer after Photodynamic Therapy
    Kanamori, Akira
    Goda, Kenichi
    Nakamura, Tetsuya
    Yamagishi, Hidetsugu
    Ohwada, Atsuko
    Abe, Keiichiro
    Suzuki, Tsunehiro
    Kondo, Masayuki
    Tanaka, Takanao
    Yamamiya, Akira
    Takimoto, Yoichi
    Hoshi, Koki
    Arisaka, Takahiro
    Sugaya, Takeshi
    Tominaga, Keiichi
    Majima, Yuichi
    Iijima, Makoto
    Irisawa, Atsushi
    INTERNAL MEDICINE, 2022, 61 (14) : 2149 - 2153
  • [26] Salvage esophagectomy for local recurrent esophageal cancer after definitive chemoradiotherapy followed by photodynamic therapy: A case report
    Hirose, Wataru
    Taniyama, Yusuke
    Fujishima, Fumiyoshi
    Sato, Chiaki
    Unno, Michiaki
    Kamei, Takashi
    INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS, 2021, 80
  • [27] Phase I study of photodynamic therapy using talaporfin sodium and diode laser for local failure after chemoradiotherapy for esophageal cancer
    Tomonori Yano
    Manabu Muto
    Kenichi Yoshimura
    Miyuki Niimi
    Yasumasa Ezoe
    Yusuke Yoda
    Yoshinobu Yamamoto
    Hogara Nishisaki
    Koji Higashino
    Hiroyasu Iishi
    Radiation Oncology, 7
  • [28] Clinical Efficacy of HiPorfin Photodynamic Therapy for Advanced Obstructive Esophageal Cancer
    Zeng, Ruifang
    Liu, Chen
    Li, Libo
    Cai, Xiaojun
    Chen, Run
    Li, Zhiwen
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2020, 19
  • [29] Clinical Practice of Photodynamic Therapy Using Talaporfin Sodium for Esophageal Cancer
    Yano, Tomonori
    Minamide, Tatsunori
    Takashima, Kenji
    Nakajo, Keiichiro
    Kadota, Tomohiro
    Yoda, Yusuke
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (13)
  • [30] Effects of photodynamic therapy for superficial esophageal squamous cell carcinoma in vivo and in vitro
    Kawazoe, Kaoru
    Isomoto, Hajime
    Yamaguchi, Naoyuki
    Inoue, Naoki
    Uehara, Ryohei
    Matsushima, Kayoko
    Ichikawa, Tatsuki
    Takeshima, Fuminao
    Nonaka, Takashi
    Nanashima, Atsushi
    Nagayasu, Takeshi
    Uehara, Masataka
    Asahina, Izumi
    Nakao, Kazuhiko
    ONCOLOGY LETTERS, 2010, 1 (05) : 877 - 882